[144] ANI Pharmaceuticals, Inc. SEC Filing
ANI Pharmaceuticals, Inc. (ANIP) Form 144 reports a proposed sale of 6,865 shares of common stock through Morgan Stanley Smith Barney LLC with an aggregate market value of $616,223.68. The filing lists the approximate number of shares outstanding as 21,688,772 and an approximate sale date of 08/18/2025 on NASDAQ.
The shares were acquired on 05/23/2024 as restricted stock from the issuer, with payment recorded on the same date. The filer reports no sales of the issuer's securities in the past three months and includes the standard representation that they do not possess undisclosed material adverse information.
- Notice filed under Rule 144 with broker identified (Morgan Stanley Smith Barney LLC)
- Full acquisition details provided: date, nature (restricted stock), and source (issuer)
- No sales in the past three months reported, clarifying recent trading activity
- None.
Insights
TL;DR: Routine Rule 144 notice for a proposed sale of restricted shares; disclosure aligns with regulatory requirements.
The filing documents a proposed sale under Rule 144 using a registered broker, naming Morgan Stanley Smith Barney LLC, and provides required details: class, quantity, acquisition date, nature of acquisition, aggregate market value, and intended sale date. The inclusion of a statement that there have been no sales in the past three months and the standard attestation about material non-public information are consistent with standard compliance practices for insiders or restricted holders preparing to sell.
TL;DR: Small, disclosed sale of restricted shares; unlikely to be materially impactful to ANIP’s capitalization.
The notice specifies 6,865 shares valued at $616,223.68 and lists 21,688,772 shares outstanding, with the shares acquired from the issuer as restricted stock on 05/23/2024. The filing contains no indication of prior recent sales and does not report any unusual transaction structures. From an investor-information standpoint, this is a transparent disclosure of a planned sale rather than a material corporate event.